New injection shows promise for controlling rare inflammatory disease
NCT ID NCT04717635
Summary
This study tested a drug called canakinumab to see if it could help control the symptoms of Adult-Onset Still's Disease (AOSD), a rare inflammatory condition. Fourteen Japanese patients received a subcutaneous injection every four weeks for at least 48 weeks. The main goal was to see if the treatment reduced disease activity and allowed patients to lower their steroid use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ONSET STILL'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Chiba, Chiba, 260 8677, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 0608648, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa-ku, 236-0004, Japan
-
Novartis Investigative Site
Iruma-gun, Saitama, 3500495, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138655, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1048560, Japan
-
Novartis Investigative Site
Mitaka, Tokyo, 181-8611, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 1608582, Japan
-
Novartis Investigative Site
Ishikawa, 9208641, Japan
Conditions
Explore the condition pages connected to this study.